STAT2 min read
STAT+: Pharmalittle: Pfizer Is Leaving The BIO Trade Group; CVS Drug-pricing Plan May Not Lower Costs For Consumers
Pfizer has decided to leave the Biotechnology Innovation Organization, dealing a blow to the biopharma trade group.
STAT1 min read
STAT+: Using AI, Scientists Create Blood Test That Measures Organ Aging And Predicts Disease Risk
Scientists developed a way to analyze the varying rates at which organs age using the distinct proteins that those organs produce and shed into the blood.
STAT1 min read
Opinion: STAT+: A Bold Approach To Pay For Weight Loss Drugs For Everyone Who Needs Them
A bold idea for how to pay for weight loss drugs for everyone who needs them — and save Medicare at the same time.
STAT1 min read
STAT+: Using Pap Smears For Earlier Ovarian Cancer Detection Shows Promise In Small New Study
A new study found Pap smears stored in a hospital could detect ovarian cancer tumors as much as nine years before the women were actually diagnosed.
STAT2 min read
STAT+: Pharmalittle: Roche To Buy Obesity-drug Developer For $2.7 Billion; Novo Nordisk Paid U.S. Doctors $26 Million Over A Decade
The booming obesity market is attracting another player, as Roche plans to acquire Carmot Therapeutics and its weight loss drug candidates.
STAT2 min read
STAT+: Pharmalittle: Pfizer Halts Development Of Twice-daily Obesity Pill; Supreme Court To Review Purdue Bankruptcy Deal
Pfizer is stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial.
STAT2 min read
STAT+: Pharmalittle: AbbVie Buys Immunogen, Maker Of Targeted Cancer Drugs; Novo Sues Two More Compounders
AbbVie will pay $10 billion for Immunogen, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.
STAT2 min read
STAT+: Pharmalittle: FDA Probes CAR-T Therapy For Links To Lymphoma; White House Official Attacks Bristol Over Medicare Price Talks
The FDA is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma.
STAT1 min readCorporate Finance
STAT+: Saudi VC Loops Novo Nordisk, Other Biotech VCs Into New Longevity Incubator
Hevolution, a Saudi investment firm focused on aging science, is launching an incubator that will bring together experts from the scientific community, pharma, and biotech VCs.
STAT1 min read
Opinion: Manufacturers Need To Be More Open About A Dangerous Alzheimer’s Drug Side Effect
Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover the drug, I have met with Alzheimer’s patients and their loved ones who are anxious to know whether they may benefit from this new treatment. They com
STAT2 min read
STAT+: Pharmalittle: More U.S. States And Cities Are Suing Insulin Makers; Biden Looks To Boost U.S. Drug Manufacturing Amid Shortages
A growing number of state and local governments across the U.S. are suing insulin makers and PBMs over claims they conspired to illegally drive up prices.
STAT2 min read
STAT+: Pharmalittle: Bioscience Job Market Is Upside Down; Sanofi And Regeneron’s Blockbuster Dupixent May Find Bigger Market
Bioscience job postings have dropped from around 19,000 in February 2022 to 10,000 in October 2023.
STAT2 min readSmall Business & Entrepreneurs
STAT+: How The CEO Of The Largest Medical Device Accelerator Molds Medtech Startups
MedTech Innovator is creating a vibrant community of innovators, injecting a youthful spirit into a somewhat bloated, stodgy industry.
STAT1 min read
STAT+: Pharmalittle: Texas Sues Pfizer Over ADHD Drugs; Merck Buys A Neuro Startup
The Texas attorney general is suing Pfizer over allegedly selling ineffective ADHD medicines to the state's Medicaid program.
STAT2 min read
STAT+: Pharmalittle: CRISPR Pioneers Reflect On Future Of Gene Editing; U.K. And Pharma Reach Deal On How NHS Pays For Drugs
The U.K. and the pharma industry reached a deal on a five-year plan outlining how the National Health Service pays for drugs.
STAT2 min read
STAT+: Pharmalittle: Woodcock To Retire From The FDA; Acrotech Urged To Speed Up Confirmatory Study Of Cancer Drugs
A FDA advisory panel urged Acrotech Biopharma to accelerate the release of trial data that could confirm benefits of its blood cancer drugs.
STAT2 min read
STAT+: Pharmalittle: U.K. Approves World’s First CRISPR-based Medicine; FDA To Review Pricey Cancer Drug Lacking Confirmatory Data
U.K. regulators approved a CRISPR-based medicine to treat sickle cell disease and beta thalassemia, ushering in a new era of genetic therapy.
STAT1 min read
STAT+: Life Scientists’ Flight To Biotech Labs Stalls Important Academic Research
The seismic shift in researchers from academic to biotech labs is already having a detrimental impact on basic research.
STAT2 min read
STAT+: Pharmalittle: German Regulator Eyes Ozempic Export Ban Amid Shortages; NIH-funded Clinical Trials Lagging Pharma’s In Enrollment
The German drug regulator is considering an export ban on Novo Nordisk's diabetes drug Ozempic as European health systems face a shortage.
STAT2 min read
STAT+: Pharmalittle: AMA Calls For Obesity Drug Coverage; Covid Rebound May Be More Common With Paxlovid Than Without
The AMA called on insurance companies, employers, and government programs to cover obesity treatments.
STAT2 min read
STAT+: Pharmalittle: Wegovy Cuts Heart Attack Risk In Milestone Trial; AstraZeneca Prioritizes U.S. For RSV Drug Amid Surge
Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark trial, affirming it offers health benefits beyond weight loss.
STAT1 min read
STAT+: Patients Loved Carbon Health’s Diabetes Program. That Couldn’t Save It
Patients loved Carbon Health's telehealth-based program for managing diabetes. That couldn't save it.
STAT2 min read
STAT+: Pharmalittle: Novo Nordisk To Spend $6 Billion To Boost Production; FDA Okays World’s First Vaccine For Chikungunya
Novo Nordisk announced a plan to spend a whopping $6 billion to expand its manufacturing capacity at its main production site in Denmark.
STAT1 min read
STAT+: What Amazon Prime’s New One Medical Offering Reveals About The Future Of Health Care
Amazon Prime members have a new offer in addition to the usual delivery and streaming services: Access to One Medical, the Amazon-owned primary care company. Members have the option, announced Wednesday, to pay an additional $9 per month, or $99 per
STAT2 min read
STAT+: Pharmalittle: Lilly Wins FDA Approval For A Weight-loss Drug; AstraZeneca Enters The Race For An Obesity Pill
Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, for which it will be sold as Zepbound.
STAT2 min read
STAT+: Pharmalittle: FTC Challenges ‘Inaccurately Or Improperly’ Listed Patents; Elliott Builds Stake In BioMarin
The FTC is challenging more than 100 patents on brand-name medicines, saying drug companies improperly or inaccurately listed them on a U.S. registry.
STAT1 min readSecurity
Opinion: STAT+: The PATCH Act’s Approach To Securing Medical Devices Actually Gives Malicious Actors A Blueprint
The PATCH Act’s recently implemented approach to securing medical devices actually gives malicious actors a blueprint.
STAT2 min read
STAT+: Pharmalittle: Vertex And U.K. At Odds Over Value Of CF Meds; French Authorities Probe Sanofi Over Alleged Market Manipulation
Vertex and a U.K. government agency are at odds again over the value of life-saving cystic fibrosis medicines.
…Or Discover Something New